- Report
- August 2025
- 180 Pages
Global
From €3484EUR$3,939USD£3,008GBP
- Report
- August 2025
- 196 Pages
Global
From €3484EUR$3,939USD£3,008GBP
- Report
- August 2025
- 186 Pages
Global
From €3135EUR$3,545USD£2,707GBP
€3484EUR$3,939USD£3,008GBP
- Report
- July 2025
- 175 Pages
Global
From €3971EUR$4,490USD£3,428GBP
- Report
- April 2025
- 250 Pages
Global
From €3971EUR$4,490USD£3,428GBP
- Report
- March 2025
- 97 Pages
Global
From €3500EUR$4,240USD£3,128GBP
- Report
- July 2024
- 200 Pages
Global
From €4377EUR$4,949USD£3,779GBP
- Report
- November 2018
- 53 Pages
Global
From €7513EUR$8,495USD£6,486GBP
- Report
- November 2021
- 844 Pages
Global
From €4422EUR$5,000USD£3,818GBP
Siponimod is a drug used to treat multiple sclerosis (MS). It is a sphingosine-1-phosphate receptor modulator, which works by blocking the action of certain immune cells that are involved in the development of MS. It is used to reduce the frequency of relapses and slow the progression of disability in people with relapsing forms of MS. It is also used to treat secondary progressive MS in adults.
Siponimod is part of a larger class of drugs known as Central Nervous System (CNS) drugs. These drugs are used to treat a variety of neurological conditions, including MS, Alzheimer's disease, Parkinson's disease, and epilepsy. CNS drugs are typically prescribed by neurologists and other healthcare professionals.
The market for Siponimod is highly competitive, with several companies offering the drug. These include Novartis, Biogen, Merck, and Teva Pharmaceuticals. Each company has its own unique formulation of the drug, which may vary in terms of efficacy and side effects. Show Less Read more